<DOC>
	<DOC>NCT02287779</DOC>
	<brief_summary>This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.</brief_summary>
	<brief_title>Safety and Tolerability Study of SHP626 in Overweight and Obese Adults</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Males that comply with any applicable contraceptive requirements or females of nonchildbearing potential No history of active or chronic disease other than that allowed by study (hypertension, hyperlipidemia and gastroesophageal reflux disease (GERD) or heartburn) Has a body mass index of 2535 kg/m2 with a body weight of greater than 140lbs (assessed at screening) No history of alcohol or substance abuse, including use of tobacco No substantial changes in eating habits or exercise routine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>